Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERTO M NIETO

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1750430419
CMS profile
306412
Location
MANSFIELD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$46,593.92

237 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERTO M NIETO

NPI 1750430419 · CMS profile ID 306412

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

MANSFIELD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750430419?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERTO M NIETO, NPI 1750430419, CMS profile ID 306412. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750430419?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ROBERTO M NIETO, NPI 1750430419, CMS profile ID 306412. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750430419?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ROBERTO M NIETO, NPI 1750430419, CMS profile ID 306412, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1750430419?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

237 matching records · $46,593.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 237 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 237.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan, Inc. $11.4410/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723741091 CMS
Allergan, Inc. $1,300.0010/09/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723741089 CMS
Supernus Pharmaceuticals, Inc. $1,500.0010/09/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748352711 CMS
Biogen, Inc. $16.1010/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737280317 CMS
Teva Pharmaceuticals USA, Inc. $11.2810/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749571975 CMS
Teva Pharmaceuticals USA, Inc. $1,680.0010/06/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749521079 CMS
Amgen Inc. $12.7610/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741289015 CMS
Allergan, Inc. $3.1010/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723741087 CMS
PFIZER INC. $20.5510/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743475021 CMS
UCB, Inc. $22.1709/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746087583 CMS
Teva Pharmaceuticals USA, Inc. $15.5009/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749571881 CMS
GENZYME CORPORATION $17.3009/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744116087 CMS
Allergan, Inc. $4.5509/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723741085 CMS
Sunovion Pharmaceuticals Inc. $18.0109/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748529133 CMS
Allergan, Inc. $14.1309/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723741083 CMS
Eisai Inc. $13.4909/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751227217 CMS
Supernus Pharmaceuticals, Inc. $1.6209/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748352707 CMS
Supernus Pharmaceuticals, Inc. $10.3809/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748352709 CMS
Neurocrine Biosciences, Inc. $25.2509/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748933159 CMS
Kyowa Kirin, Inc. $1,080.0009/17/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746881725 CMS
Upsher-Smith Laboratories LLC $22.1509/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733048653 CMS
Lilly USA, LLC $14.7209/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728625909 CMS
EMD Serono, Inc. $28.5609/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751289313 CMS
Jazz Pharmaceuticals Inc. $24.9609/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744462465 CMS
Lundbeck LLC $14.5209/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747558607 CMS
Allergan, Inc. $3.4509/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723741081 CMS
SK Life Science, Inc. $19.4909/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733065475 CMS
Arbor Pharmaceuticals, Inc. $23.9909/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735723199 CMS
Biogen, Inc. $18.3809/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737280311 CMS
Amgen Inc. $20.5209/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741289013 CMS
Allergan, Inc. $12.8109/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723741079 CMS
Jazz Pharmaceuticals Inc. $19.2308/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744460001 CMS
Teva Pharmaceuticals USA, Inc. $19.4508/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749572219 CMS
Supernus Pharmaceuticals, Inc. $8.3208/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748352705 CMS
Upsher-Smith Laboratories LLC $22.4008/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733045699 CMS
Allergan, Inc. $975.0008/25/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723741077 CMS
Neurocrine Biosciences, Inc. $24.0708/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748933157 CMS
Allergan, Inc. $975.0008/20/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723741073 CMS
Allergan, Inc. $19.3208/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723741075 CMS
Lilly USA, LLC $13.0108/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728619149 CMS
Biogen, Inc. $23.6208/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737280321 CMS
EMD Serono, Inc. $660.0008/19/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751287369 CMS
UCB, Inc. $36.7308/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746084181 CMS
Kyowa Kirin, Inc. $18.4908/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746881719 CMS
Supernus Pharmaceuticals, Inc. $2.9508/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748352701 CMS
Supernus Pharmaceuticals, Inc. $9.1608/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748352703 CMS
Allergan, Inc. $975.0008/06/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723741071 CMS
Avanir Pharmaceuticals, Inc. $19.5008/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722212757 CMS
Harmony Biosciences LLC $19.1808/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750475059 CMS
EMD Serono, Inc. $26.1008/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751283627 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $73,831.48 271
PY2020 $46,593.92 237
PY2021 $44,327.22 269
PY2022 $34,237.07 203
PY2023 $18,631.38 108
PY2024 $3,068.08 172
PY2025 $25,254.19 227

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Principal investigator $33,938.50 25
PY2019 Principal investigator $44,133.02 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eisai Inc. $1,132.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749126355
Principal investigator 1 Eisai Inc. $1,604.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127177
Principal investigator 1 Eisai Inc. $918.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127179
Principal investigator 1 Eisai Inc. $531.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127181
Principal investigator 1 Eisai Inc. $75.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127183
Principal investigator 1 Eisai Inc. $1,783.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127185
Principal investigator 1 Eisai Inc. $75.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127187
Principal investigator 1 Eisai Inc. $531.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127189
Principal investigator 1 Eisai Inc. $868.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749128231
Principal investigator 1 Eisai Inc. $1,733.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749128469
Principal investigator 1 Eisai Inc. $1,733.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749128471
Principal investigator 1 Eisai Inc. $1,733.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749128473
Principal investigator 1 Eisai Inc. $1,733.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749128475
Principal investigator 1 Eisai Inc. $1,733.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749128477
Principal investigator 1 Eisai Inc. $9,173.70 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749129683
Principal investigator 1 Eisai Inc. $253.40 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130377
Principal investigator 1 Eisai Inc. $113.20 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130393
Principal investigator 1 Eisai Inc. $7.50 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130397
Principal investigator 1 Eisai Inc. $12.50 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130455
Principal investigator 1 Eisai Inc. $25.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130483
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,250.80 03/11/2020 Non-covered Recipient Entity
NEUROLOGICAL ASSOCIATES OF ALRINGTON PA
LONG TERM PROSPECTIVE MULTINATIONAL PARALLEL COHORT STUDY MONITORING SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY STARTED WITH FINGOLIMOD ONCE DAILY OR TREATED WITH ANOTHER APPROVED DISEASE MODIFYING THERAPY No dispute reported 06/30/2026 721493843
Principal investigator 1 Eisai Inc. $1,500.00 02/11/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127269
Principal investigator 1 Eisai Inc. $300.00 02/11/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127271
Principal investigator 1 UCB SA $2,053.00 02/04/2020 Non-covered Recipient Entity
ARLINGTON GASTROENTEROLOGY ASSOCIATES, LLP
MULTICENTER 1-YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAM No dispute reported 06/30/2026 746126279
Principal investigator 1 UCB SA $1,067.40 02/04/2020 Non-covered Recipient Entity
ARLINGTON GASTROENTEROLOGY ASSOCIATES, LLP
MULTICENTER 1-YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAM No dispute reported 06/30/2026 746128421